Search: onr:"swepub:oai:prod.swepub.kib.ki.se:118018589" >
Phospholipase C{bet...
Phospholipase C{beta}3 in mouse and human dorsal root ganglia and spinal cord is a possible target for treatment of neuropathic pain
-
- Shi, TJS (author)
- Karolinska Institutet
-
Liu, SXL (author)
-
- Hammarberg, H (author)
- Karolinska Institutet
-
show more...
-
Watanabe, M (author)
-
- Xu, ZQD (author)
- Karolinska Institutet
-
- Hokfelt, T (author)
- Karolinska Institutet
-
show less...
-
(creator_code:org_t)
- 2008-12-16
- 2008
- English.
-
In: Proceedings of the National Academy of Sciences of the United States of America. - : Proceedings of the National Academy of Sciences. - 1091-6490. ; 105:50, s. 20004-20008
- Related links:
-
http://www.pnas.org/...
-
show more...
-
http://kipublication...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Treatment of neuropathic pain is a major clinical problem. This study shows expression of phospholipase ß3 (PLCß3) in mouse and human DRG neurons, mainly in small ones and mostly with a nonpeptidergic phenotype. After spared nerve injury, the pain threshold was strongly reduced, and systemic treatment of such animals with the unselective PLC inhibitor U73122 caused a rapid and long-lasting (48-h) increase in pain threshold. Thus, inhibition of PLC may provide a way to treat neuropathic pain.
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database